Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 16/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.62 |
| ▸ | ITK | Q08881 | 2/20 | 0.57 |
| ▸ | GRK5 | P34947 | 1/20 | 0.55 |
| ▸ | MAPK3 | P27361 | 2/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.53 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16780962 | 0.85 | EGFR (0.61) | EGFRALKITKGRK5MAPK3 | |
| SCHEMBL15600773 | 0.84 | EGFR (0.55) | EGFRALKITKGRK5MAPK3 | |
| SCHEMBL21558130 | 0.83 | EGFR (0.65) | EGFRALKMAPK3INSRERBB2 | |
| SCHEMBL21558107 | 0.81 | ALK (0.59) | EGFRALKMAPK3INSRERBB2 | |
| SCHEMBL21557833 | 0.80 | ALK (0.63) | EGFRALKMAPK3INSR | |
| SCHEMBL21557824 | 0.80 | ALK (0.63) | EGFRALKMAPK3INSR | |
| SCHEMBL21557851 | 0.79 | MAPK3 (0.64) | EGFRALKMAPK3INSRERBB2 | |
| SCHEMBL14982975 | 0.79 | ALK (0.84) | EGFRALKINSRERBB2ERBB4 | |
| SCHEMBL17792759 | 0.79 | EGFR (0.76) | EGFRALKMAPK3ERBB2ERBB3 | |
| SCHEMBL13726979 | 0.78 | EGFR (0.59) | EGFRALKITKGRK5MAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2844642-B1 | COMPOUNDS FOR INHIBITING CELL PROLIFERATION IN EGFR-DRIVEN CANCERS | ARIAD PHARMA INC (US) | 2019-11-13 | — | — | EP | disclosed |